Stirling Products to trial R-salbutamol in Canadian pigs
Stirling Products’ North American subsidiary has signed an agreement with Canada’s national research council for a trial of its lead candidate R-salbutamol in pigs.
The trial will begin next month in 40 pigs at a commercial production facility in Canada. It will be compared with ractopamine, another beta agonist used to promote lean meat production in pigs. R-salbutamol is a beta agonist derived from the R isomer of salbutamol, a known metabolic modifier which diverts energy from fat production into increased muscle mass.
Stirling, which in February appointed a new board and managing director, is also in a joint venture with Zodiac Capital, a boutique investment group. Zocap has rights to a range of phyto-pharmaceutical products developed in the Ukraine.
Related website
• Stirling Products
Join 18,000+ subscribers
Subscribe to our newsletter to stay updated about all the need-to-know content in the pigsector, three times a week.
